Abstract
Superparamagnetic iron oxide (SPIO; AMI-25 from Eiken Chemical Co.) have been known to offer excellent tumor-liver contrast in liver MR imaging by reducing the signal intensity only of the liver. To investigate the duration of liver signal decrease caused by AMI-25, 15 patients underwent MR imaging three times; before, 1 hour after, and at the different elapsed time after the drug administration (4-9 hours, 22-26 hours, and 47-49 hours). The liver darkness and the contribution of the drug to hepatic tumor detection were subjectively ranked and liver signal-to-noise ratio (SNR) and tumor-liver contrast-to-noise ratio (CNR) were obtained by the region of interest, and compared among groups with different elapsed time. Both liver darkness and SNR were maintained up to 4-9 hours after the drug administration, and both the contribution to the tumor detection and CNR showed the similar results. Our results show that effect of AMI-25 could be maintained at least several hours after the drug administration, lasting longer than previously thought.
| Original language | English |
|---|---|
| Pages (from-to) | 713-724 |
| Number of pages | 12 |
| Journal | Japanese Pharmacology and Therapeutics |
| Volume | 22 |
| Issue number | 1 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Time course of the liver enhancement by a novel MR contrast agent 'AMI- 25'. / Tanimoto, Akihiro; Yuasa, Y.; Izutsu, M.; Sato, Y.; Ohkawa, S.; Hiramatsu, K.
In: Japanese Pharmacology and Therapeutics, Vol. 22, No. 1, 1994, p. 713-724.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Time course of the liver enhancement by a novel MR contrast agent 'AMI- 25'
AU - Tanimoto, Akihiro
AU - Yuasa, Y.
AU - Izutsu, M.
AU - Sato, Y.
AU - Ohkawa, S.
AU - Hiramatsu, K.
PY - 1994
Y1 - 1994
N2 - Superparamagnetic iron oxide (SPIO; AMI-25 from Eiken Chemical Co.) have been known to offer excellent tumor-liver contrast in liver MR imaging by reducing the signal intensity only of the liver. To investigate the duration of liver signal decrease caused by AMI-25, 15 patients underwent MR imaging three times; before, 1 hour after, and at the different elapsed time after the drug administration (4-9 hours, 22-26 hours, and 47-49 hours). The liver darkness and the contribution of the drug to hepatic tumor detection were subjectively ranked and liver signal-to-noise ratio (SNR) and tumor-liver contrast-to-noise ratio (CNR) were obtained by the region of interest, and compared among groups with different elapsed time. Both liver darkness and SNR were maintained up to 4-9 hours after the drug administration, and both the contribution to the tumor detection and CNR showed the similar results. Our results show that effect of AMI-25 could be maintained at least several hours after the drug administration, lasting longer than previously thought.
AB - Superparamagnetic iron oxide (SPIO; AMI-25 from Eiken Chemical Co.) have been known to offer excellent tumor-liver contrast in liver MR imaging by reducing the signal intensity only of the liver. To investigate the duration of liver signal decrease caused by AMI-25, 15 patients underwent MR imaging three times; before, 1 hour after, and at the different elapsed time after the drug administration (4-9 hours, 22-26 hours, and 47-49 hours). The liver darkness and the contribution of the drug to hepatic tumor detection were subjectively ranked and liver signal-to-noise ratio (SNR) and tumor-liver contrast-to-noise ratio (CNR) were obtained by the region of interest, and compared among groups with different elapsed time. Both liver darkness and SNR were maintained up to 4-9 hours after the drug administration, and both the contribution to the tumor detection and CNR showed the similar results. Our results show that effect of AMI-25 could be maintained at least several hours after the drug administration, lasting longer than previously thought.
UR - http://www.scopus.com/inward/record.url?scp=0028107665&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028107665&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028107665
VL - 22
SP - 713
EP - 724
JO - Japanese Pharmacology and Therapeutics
JF - Japanese Pharmacology and Therapeutics
SN - 0386-3603
IS - 1
ER -